CRISPR (CRSP) Rated Overweight on Gene Editing Growth [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
Sandler boosted its price target for CRISPR Therapeutics AG (NASDAQ:CRSP) to $110 from $105 on March 17, retaining an Overweight rating in response to the company's convertible note issuance. CRISPR Therapeutics AG (NASDAQ:CRSP) raised $600 million in convertible notes due in March 2031, convertible at $76.56 per share and with an effective interest rate of 1.73%. The company also allowed initial purchasers to pick up an extra $50 million in notes, with the transaction set to finalize in March of this year. Moreover, CRISPR Therapeutics AG (NASDAQ:CRSP) plans to disclose Phase I data on zugo-cel in autoimmune diseases and B-cell lymphoma in the latter half of 2026. The company also plans to begin Phase I research on CTX340 in the first half of 2026 and CTX460 in mid-2026. Meanwhile, in the second half of 2026, CRISPR Therapeutics AG (NASDAQ:CRSP) will provide Phase Ib data on CTX310 and proof-of-concept Phase II data on CTX611 in patients undergoing total knee replacement. CRISP
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts [Yahoo! Finance]Yahoo! Finance
- I Expect Crispr Therapeutics To Break Out As 2026 Revenue Exceeds Expectations [Seeking Alpha]Seeking Alpha
- Is CRISPR Therapeutics (CRSP) Attractive After Recent Share Price Pullback? [Yahoo! Finance]Yahoo! Finance
- CRISPR Therapeutics (CRSP) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Learn From The Leaders: Biotech Stock Research On Seeking Alpha | Ed Ingham's 6-Tab Method [Seeking Alpha]Seeking Alpha
CRSP
Earnings
- 2/12/26 - Miss
CRSP
Sec Filings
- 4/2/26 - Form PRE
- 3/24/26 - Form 4
- 3/24/26 - Form 4
- CRSP's page on the SEC website